Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Inmed Pharmaceuticals Inc. is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners across 3 distinct art units. This one to one ratio between actions, examiners, and art units indicates a highly decentralized prosecution profile. Each pending action is being reviewed by a different individual in a different administrative group, which requires a versatile legal strategy to address varying examiner styles and unit-specific norms.
Liyuan Mou is the busiest examiner for this portfolio, with 1 pending office action under review. Since each of the 3 distinct examiners is handling exactly 1 pending office action, the workload is perfectly distributed. This arrangement means that the company's progress in the Biotechnology & Pharmaceuticals sector is not tied to any single examiner's desk. The involvement of 3 distinct art units suggests that the company's pharmaceutical innovations are being evaluated from three different technical perspectives within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| REILLY, SOPHIA JANE | 1 | 60.0% | +49.4% |
| REGA, KYLE THOMAS | 1 | 63.0% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033187 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | MOU, LIYUAN | 45d overdue |
| 17606003 | COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION | REILLY, SOPHIA JANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033187 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | MOU, LIYUAN | 45d overdue |
| 17606003 | COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION | REILLY, SOPHIA JANE | — |
| 17436548 | COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM | REGA, KYLE THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1627 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033187 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | MOU, LIYUAN | 1628 | §103§112 | Final Rejection | 45d overdue | Pending | Apr 21, 2023 |
| 17606003 | COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION | REILLY, SOPHIA JANE | 1627 | §101§102§103§112Other | Non-Final OA | — | Pending | Oct 22, 2021 |
| 17436548 | COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | — | Pending | Sep 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInmed Pharmaceuticals Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Liyuan Mou has the most, with 1 of Inmed Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
